About

Placental growth fActor Repeat sampling for reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia (PARROT-2)

 

PARROT-2 is a multi-centre randomised controlled trial of revealed versus concealed repeat placental growth factor (PlGF)-based testing in women presenting with suspected pre-eclampsia between 22+0 and 35+6 weeks' gestation. 

 

All women recruited to the trial will have an initial PlGF-based test, as recommended by the updated NICE Guideline on Hypertension in Pregnancy. Women may then be recruited into either the randomised trial of repeat testing, or the observational cohort, (if they decline randomisation).


The primary outcome is a composite of perinatal severe adverse outcomes, comprising stillbirth, early neonatal death or neonatal unit admission. Secondary descriptive perinatal and maternal adverse outcomes will also be collected.